GRI

GLP-1 analogues indicated in the treatment of obesity: ANSM changes their conditions of prescription and issuance

News Healthcare & Pharma Reports
Date: 20th Jun, 2025 Source: French National Agency for the Safety of Medicines and Health Products (ANSM) Country: France Original Source

Brief

"On June 23, 2025, the French National Agency for the Safety of Medicines and Health Products (ANSM) made changes to the conditions of prescription and issuance of GLP-1 analogues indicated in the treatment of obesity. These medications, previously available only by prescription from certain doctors, can now be prescribed by any doctor according to approved medical practices, aiming to improve patient access to these treatments."

This content is restricted.

Highlights content goes here...

This content is restricted.

French National Agency for the Safety of Medicines and Health Products (ANSM)

Quick Insight
RADA.AI
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested
Related Documents
NSA, CISA, and Others Release a Shared Vision of Software Bill of Materials (SBOM)
Date: 3rd Sep, 2025 Source: National Security Agency (NSA) Country: USA
News Cybersecurity Reports
Artificial Intelligence sector study
Date: 3rd Sep, 2025 Source: Department for Science, Innovation & Technology Country: United Kingdom
News Artificial Intelligence Reports
The increase in India’s electricity production is remarkable
Date: 2nd Sep, 2025 Source: Ministry of Trade (Ticaret Bakanlığı) Country: Turkey
News Consumer protection Reports

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Click here

Enter your Email

Enter your registered username/email id.

Enter your Email

Enter your email id below to signup.
Individual Plan
  • Designed for Growing Compliance Teams
$125 / month OR $1250 / year
Features
  • • Coverage for 20 jurisdictions
  • • Monitoring from 500+ regulatory authorities
  • • AI compliance summaries
  • • RaDa.ai : Single-Role
Best for: Researchers, Legal professionals, Academics
Subscribe Now
Enterprise Plan
  • Perfect for Global Enterprises
Contact for Pricing
Features
  • • Custom jurisdictional coverage
  • • Custom monitoring of regulatory authorities
  • • RaDa.ai : Customizable multi-role
  • • Custom reporting and dashboard capabilities
  • • API access for seamless integration
Best for: Law Firms, Corporations, Government Bodies
Contact Sales